Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) EBT Margin: 2014-2020

Historic EBT Margin for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to 1,198.01%.

  • Larimar Therapeutics' EBT Margin fell 142899.00% to 1,198.01% in Q1 2020 from the same period last year, while for Mar 2020 it was 2,291.13%, marking a year-over-year decrease of 71779.00%. This contributed to the annual value of 2,572.54% for FY2019, which is 64827.00% down from last year.
  • Per Larimar Therapeutics' latest filing, its EBT Margin stood at 1,198.01% for Q1 2020, which was down 40.66% from 2,018.78% recorded in Q4 2019.
  • Larimar Therapeutics' 5-year EBT Margin high stood at 163,875.00% for Q4 2017, and its period low was 1,198.01% during Q1 2020.
  • Over the past 3 years, Larimar Therapeutics' median EBT Margin value was 2,908.82% (recorded in 2018), while the average stood at 2,701.23%.
  • Its EBT Margin has fluctuated over the past 5 years, first skyrocketed by 15,321,314bps in 2017, then tumbled by 16,096,618bps in 2018.
  • Quarterly analysis of 5 years shows Larimar Therapeutics' EBT Margin stood at 10,661.86% in 2016, then surged by 15,321,314bps to 163,875.00% in 2017, then crashed by 16,096,618bps to 2,908.82% in 2018, then slumped by 89,003bps to 2,018.78% in 2019, then slumped by 142,899bps to 1,198.01% in 2020.
  • Its last three reported values are 1,198.01% in Q1 2020, 2,018.78% for Q4 2019, and 3,023.71% during Q3 2019.